Jul 22, 2021
Evolus to Report Second Quarter 2021 Results and Provide Business Update
Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184 (
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com.
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Vice President, Investor Relations
Chief Marketing Officer